BRPI0815050A8 - Avidina oxidada com tempo de permanência elevado em tecidos tratados, complexo compreendendo a referida avidina e uso dos mesmos, composição farmacêutica, kit, bem como processo de oxidação de avidina - Google Patents
Avidina oxidada com tempo de permanência elevado em tecidos tratados, complexo compreendendo a referida avidina e uso dos mesmos, composição farmacêutica, kit, bem como processo de oxidação de avidinaInfo
- Publication number
- BRPI0815050A8 BRPI0815050A8 BRPI0815050A BRPI0815050A BRPI0815050A8 BR PI0815050 A8 BRPI0815050 A8 BR PI0815050A8 BR PI0815050 A BRPI0815050 A BR PI0815050A BR PI0815050 A BRPI0815050 A BR PI0815050A BR PI0815050 A8 BRPI0815050 A8 BR PI0815050A8
- Authority
- BR
- Brazil
- Prior art keywords
- avidin
- treated tissues
- oxidation
- kit
- pharmaceutical composition
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Diabetes (AREA)
- Immunology (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Optics & Photonics (AREA)
- Physics & Mathematics (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Psychiatry (AREA)
- Urology & Nephrology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Vascular Medicine (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Inorganic Chemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
AVIDINA OXIDADA COM TEMPO DE PERMANÊNCIA ELEVADO EM TECIDOS TRATADOS, COMPLEXO COMPREENDENDO A REFERIDA AVIDINA E USO DOS MESMOS, COMPOSIÇÃO FARMACÊUTICA, KIT, BEM COMO PROCESSO DE OXIDAÇÃO DE AVIDINA. A presente invenção refere-se a avidinas quimicamente modificadas que possuem maior permanência nos tecidos tratados em comparação com a avidina tipo silvestre. A oxidação de avidina é executada pela incubação de periodato na presença do ligante de baixa afinidade HABA que, ocupando os sítios de ligação da biotina, impede a desnaturação da proteína durante a etapa de oxidação. A oxidação de periodato gera grupos de CHO de abertura do anel de manose de avidina que, uma vez injetados, reagem com os resíduos de NH2 do tecido para formar bases de Schiff estáveis. As avidinas ancoradas mantêm a capacidade de ligar os agentes biotinilados dotados de atividade terapêutica, como biotinas marcadas radiotivamente, células-tronco e células somáticas, úteis para braquiterapias como INtraoperative Avidination Radionuclide Therapy (IARTR) ou doenças degenerativas ou genéticas.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP07113733 | 2007-08-02 | ||
| EP08157473 | 2008-06-03 | ||
| PCT/EP2008/059260 WO2009016031A1 (en) | 2007-08-02 | 2008-07-16 | Oxidized avidin with high residency time in the treated tissues |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| BRPI0815050A2 BRPI0815050A2 (pt) | 2015-02-10 |
| BRPI0815050A8 true BRPI0815050A8 (pt) | 2017-12-26 |
| BRPI0815050B1 BRPI0815050B1 (pt) | 2020-01-28 |
| BRPI0815050B8 BRPI0815050B8 (pt) | 2021-05-25 |
Family
ID=39734214
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0815050A BRPI0815050B8 (pt) | 2007-08-02 | 2008-07-16 | avidina oxidada com tempo de permanência elevado em tecidos tratados, complexo compreendendo a referida avidina e uso dos mesmos, composição farmacêutica, kit, bem como processo de oxidação de avidina |
Country Status (25)
| Country | Link |
|---|---|
| US (1) | US8562947B2 (pt) |
| EP (1) | EP2185203B1 (pt) |
| JP (1) | JP5577248B2 (pt) |
| KR (1) | KR101544628B1 (pt) |
| CN (1) | CN101772353B (pt) |
| AR (1) | AR067771A1 (pt) |
| AU (1) | AU2008281901B2 (pt) |
| BR (1) | BRPI0815050B8 (pt) |
| CA (1) | CA2694391C (pt) |
| DK (1) | DK2185203T3 (pt) |
| EA (1) | EA017017B1 (pt) |
| ES (1) | ES2625815T3 (pt) |
| HR (1) | HRP20170735T1 (pt) |
| HU (1) | HUE032093T2 (pt) |
| IL (1) | IL203321A (pt) |
| LT (1) | LT2185203T (pt) |
| MX (1) | MX2010001302A (pt) |
| MY (1) | MY155347A (pt) |
| NZ (1) | NZ582711A (pt) |
| PL (1) | PL2185203T3 (pt) |
| PT (1) | PT2185203T (pt) |
| SG (1) | SG183076A1 (pt) |
| SI (1) | SI2185203T1 (pt) |
| TW (1) | TWI441650B (pt) |
| WO (1) | WO2009016031A1 (pt) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9573982B2 (en) * | 2010-12-28 | 2017-02-21 | Japan Tobacco Inc. | Modified tamavidin |
| ES2729549T3 (es) * | 2011-08-02 | 2019-11-04 | Alfasigma Spa | Composición farmacéutica de avidina oxidada adecuada para la inhalación |
| JP2014001204A (ja) * | 2012-05-23 | 2014-01-09 | Kumamoto Univ | 腫瘍細胞選択的抗がん剤 |
| JP2016511747A (ja) | 2013-01-04 | 2016-04-21 | マサチューセッツ インスティテュート オブ テクノロジー | ナノ粒子表面結合に基づく薬物の組織への送達 |
| US10925852B2 (en) | 2015-06-30 | 2021-02-23 | The Trustees Of Columbia University In The City Of New York | Talc-bound compositions and uses thereof |
| EP3458097A4 (en) * | 2016-05-19 | 2020-01-08 | University of Miami | TARGETED DELIVERY OF THERAPEUTIC AGENTS AND IMAGING REAGENTS TO CANCER PANCREAS CELLS |
| US11313855B2 (en) * | 2018-09-25 | 2022-04-26 | Siemens Healthcare Diagnostics Inc. | Methods and compositions for removing biotin interference from assays using conjugated molecular traps |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE254631T1 (de) * | 1993-12-07 | 2003-12-15 | Neorx Corp | Pretargeting verfahren und mitteln |
| US5716594A (en) * | 1994-06-06 | 1998-02-10 | The Jmde Trust | Biotin compounds for targetting tumors and sites of infection |
| US8021667B2 (en) * | 1994-11-16 | 2011-09-20 | Macfarlane Burnet Institute For Medical Research And Public Health Ltd | Compositions for immunotherapy and uses thereof |
| US6632929B1 (en) * | 1998-11-10 | 2003-10-14 | Yeda Research And Development Co. Ltd | Avidin derivatives and uses thereof |
| US7001994B2 (en) * | 2001-01-18 | 2006-02-21 | Genzyme Corporation | Methods for introducing mannose 6-phosphate and other oligosaccharides onto glycoproteins |
| US20040101901A1 (en) * | 2002-11-27 | 2004-05-27 | Piotr Tabaczewski | Novel lipophilic complexes for insertion of receptors into lipid membranes |
| ITRM20030196A1 (it) | 2003-04-24 | 2004-10-25 | Sigma Tau Ind Farmaceuti | Uso di reagenti per la preparazione di un medicamento |
-
2008
- 2008-07-16 US US12/670,925 patent/US8562947B2/en active Active
- 2008-07-16 SG SG2012054938A patent/SG183076A1/en unknown
- 2008-07-16 SI SI200831808A patent/SI2185203T1/sl unknown
- 2008-07-16 WO PCT/EP2008/059260 patent/WO2009016031A1/en not_active Ceased
- 2008-07-16 PL PL08775109T patent/PL2185203T3/pl unknown
- 2008-07-16 DK DK08775109.5T patent/DK2185203T3/da active
- 2008-07-16 BR BRPI0815050A patent/BRPI0815050B8/pt not_active IP Right Cessation
- 2008-07-16 JP JP2010518601A patent/JP5577248B2/ja not_active Expired - Fee Related
- 2008-07-16 HR HRP20170735TT patent/HRP20170735T1/hr unknown
- 2008-07-16 NZ NZ582711A patent/NZ582711A/en not_active IP Right Cessation
- 2008-07-16 EA EA201070216A patent/EA017017B1/ru unknown
- 2008-07-16 AU AU2008281901A patent/AU2008281901B2/en not_active Ceased
- 2008-07-16 EP EP08775109.5A patent/EP2185203B1/en active Active
- 2008-07-16 CN CN2008801016692A patent/CN101772353B/zh not_active Expired - Fee Related
- 2008-07-16 CA CA2694391A patent/CA2694391C/en active Active
- 2008-07-16 ES ES08775109.5T patent/ES2625815T3/es active Active
- 2008-07-16 MX MX2010001302A patent/MX2010001302A/es active IP Right Grant
- 2008-07-16 HU HUE08775109A patent/HUE032093T2/en unknown
- 2008-07-16 LT LTEP08775109.5T patent/LT2185203T/lt unknown
- 2008-07-16 KR KR1020107004513A patent/KR101544628B1/ko not_active Expired - Fee Related
- 2008-07-16 PT PT87751095T patent/PT2185203T/pt unknown
- 2008-07-16 MY MYPI2010000136A patent/MY155347A/en unknown
- 2008-07-18 TW TW097127328A patent/TWI441650B/zh not_active IP Right Cessation
- 2008-08-01 AR ARP080103343A patent/AR067771A1/es active IP Right Grant
-
2010
- 2010-01-14 IL IL203321A patent/IL203321A/en active IP Right Grant
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0815050B8 (pt) | avidina oxidada com tempo de permanência elevado em tecidos tratados, complexo compreendendo a referida avidina e uso dos mesmos, composição farmacêutica, kit, bem como processo de oxidação de avidina | |
| Janzen et al. | Unusual histone modifications in Trypanosoma brucei | |
| EP1581656A4 (en) | MODULATION OF THE EXPRESSION OF HIF1a AND HIF2a | |
| BRPI0512535A (pt) | compostos de piperidinas n-substituìdas, suas composições e métodos de modulações | |
| BRPI0508931A (pt) | ácido nucleico isolado, composição farmacêutica e usos de uma quantidade eficaz de um primeiro ligante de ácido nucleico | |
| EA200900154A1 (ru) | Фосфинатные соединения (варианты), фармацевтическая композиция на их основе, способ лечения вирусного гепатита с с ее помощью, терапевтическое средство на их основе и названные соединения для изготовления лекарства от вирусного гепатита с | |
| BRPI0412343A (pt) | derivados de piridazina e seu uso como agentes terapêuticos | |
| BRPI0410748A (pt) | agentes citotóxicos melhorados compreendendo novos maytansinóides | |
| BRPI0509172A (pt) | pelo menos uma entidade quìmica, composição farmacêutica, métodos para tratar um paciente, para inibir pelo menos uma enzima que utiliza atp, e para tratar pelo menos uma doença, uso de pelo menos uma entidade quìmica, e, método para a fabricação de um medicamento | |
| BRPI0510394A (pt) | inibidores de 11-beta-hidroxiesteróide desidrogenase tipo 1 | |
| DK1620140T3 (da) | Injicerbare tværbundne polymere præparater samt deres anvendelse | |
| BRPI0515482A (pt) | derivados heterocìclicos e seus usos como agentes terapêuticos | |
| IL169896A0 (en) | Methods and compositions for administering therapeutic and diagnostic agents | |
| GT200800184A (es) | Aminotetrahidropiranos como inhibidores de dipeptidil peptidasa-iv para el tratamiento o prevencion de diabetes. | |
| BRPI0606817A2 (pt) | derivados de piridazina e seu uso como agentes terapêuticos | |
| BRPI0410235A (pt) | inibição de pde4, composto, composição farmacêutica, método para efetuar a inibição da enzima pde4, incrementar a cognição e/ou tratar a psicose em um paciente, método para o tratamento de um paciente que tem uma doença que envolve nìveis de camp diminuìdos, método para o tratamento de um paciente que sofre de uma doença alérgica ou inflamatória e método para o tratamento de um paciente que sofre de neurodegeneração resultante de uma doença ou de um ferimento | |
| NO20075245L (no) | Eliminasjon av heterogen eller blandet cellepopulasjon i tumorer | |
| BR112015012366A8 (pt) | antagonistas de cxcr7, uso dos mesmos, composição farmacêutica, bem como métodos para detectar níveis elevados de cxcr7 em uma amostra e para imagear um tumor, órgão, ou tecido | |
| BRPI0410979A (pt) | composto, composição farmacêutica, e, métodos para tratar uma doença em um animal mediada pela catepsina s e para tratar um paciente submetido a uma terapia | |
| BRPI0207961B8 (pt) | uso de análogos de epotilona e capecitabina para fabricar medicamento para tratar tumores cancerosos sólidos e kit compreendendo os referidos compostos. | |
| EA200601212A1 (ru) | Ингибиторы фосфодиэстеразы, получение и их терапевтическое применение | |
| BRPI0515577A (pt) | compostos de carbonila que podem ser empregados como inibidores de fator xa de coagulação | |
| WO2005112981A3 (en) | Compositions and methods for the stimulation or enhancement of bone formation and the self-renewal of cells | |
| BRPI0411098A (pt) | benzofuranocarboxamidas, com atividade pi3k, como agentes terapêuticos | |
| BRPI0409926A (pt) | saposina c-dops: um agente antitumor |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B25A | Requested transfer of rights approved |
Owner name: ALFASIGMA S.P.A. (IT) |
|
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B06T | Formal requirements before examination [chapter 6.20 patent gazette] | ||
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 28/01/2020, OBSERVADAS AS CONDICOES LEGAIS. |
|
| B16C | Correction of notification of the grant [chapter 16.3 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 16/07/2008 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF |
|
| B25G | Requested change of headquarter approved |
Owner name: ALFASIGMA S.P.A. (IT) |
|
| B21F | Lapse acc. art. 78, item iv - on non-payment of the annual fees in time |
Free format text: REFERENTE A 17A ANUIDADE. |
|
| B24J | Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12) |
Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2840 DE 10-06-2025 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |